CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation. Circulation [Internet]. 2014;129(19). http://circ.ahajournals.org/content/early/2014/02/19/CIRCULATIONAHA.113.002779.abstract

The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. Sci Signal. 2013;6(282):ra52. 

Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, u. a.. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell [Internet]. 2010;18(6):630 - 40. http://view.ncbi.nlm.nih.gov/pubmed/21130043

Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, u. a.. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, u. a.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522

Inhibiton of VEGF-C-induced VEGFR-3 activity and lymphatic endothelial cell function by the tyrosine kinase inhibitor AZD2171. In 98th Annual Meeting of the American-Association-for-Cancer-Research [Internet]. Los Angeles, CA: American Association for Cancer Research; 2007. http://dx.doi.org/10.1158/0008-5472.CAN-07-5809

He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, u. a.. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292